Trial Profile
A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Doxorubicin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions
- 02 Aug 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 02 Aug 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 05 Jan 2022 Planned End Date changed from 30 Jul 2022 to 31 Dec 2022.